NRX Pharmaceuticals Newsroom

12 Health Care Stocks Moving In Thursday's Intraday Session

GainersLucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. SINTX Techs (NASDAQ:SINT) sha

BenzingaMay 16 12:31 ET

NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal

TipRanksMay 16 06:13 ET

Earnings Call Summary | NRX Pharmaceuticals(NRXP.US) Q1 2024 Earnings Conference

The following is a summary of the NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript:Financial Performance:NRx Pharmaceuticals reported a Q1 2024 net loss of $6.5 million, a reduction o

moomoo AIMay 15 03:11 ET · Conference Call

Express News | NRX Pharmaceuticals Q1 EPS $(0.74) Misses $(0.37) Estimate

BenzingaMay 14 16:37 ET

10-Q: Quarterly report

SEC announcementMay 14 16:36 ET · Announcements

NRX Pharmaceuticals 1Q Loss $6.5M >NRXP

NRX Pharmaceuticals 1Q Loss $6.5M >NRXP

Dow JonesMay 14 16:10 ET

Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) Reports First Quarter 2024 Financial Results and Provides Business Update

ReutersMay 14 16:01 ET

Notable Earnings After Tuesday's Close

Seeking AlphaMay 13 17:35 ET

Express News | NRX Pharmaceuticals Inc: Eyes First Commercial Revenue in 2024

ReutersMay 8 09:57 ET

NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update

Yahoo FinanceMay 8 09:55 ET

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it...

PR NewswireMay 8 08:30 ET

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024

RADNOR, Pa., May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will rele

PR NewswireMay 7 16:01 ET

NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data

By Chris Wack NRx Pharmaceuticals shares were up 38% to $2.90 after the company said it saw a statistically significant safety advantage of NRX-101 compared to the standard of care comparator in its

WSJMay 6 13:34 ET

12 Health Care Stocks Moving In Monday's Intraday Session

GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc

BenzingaMay 6 12:31 ET

NRx Pharmaceuticals Plans To Seek Accelerated Approval Of NRX-101 - Quick Facts

RTTNewsMay 6 09:13 ET

NRx Pharmaceuticals Climbs on Positive Results From Its Bipolar Depression Treatment Trial

NRx Pharmaceuticals (NASDAQ:NRXP) shares rise about 5% premarket after the company announced a statistically significant safety advantage of NRX-101 compared to the standard of care comparator in its recently completed clinical trial in patients with suicidal bipolar depression.

Seeking AlphaMay 6 08:52 ET

Express News | NRx Pharmaceuticals Announces Final Clinical Trial Results; Believes Demonstration Of Reduced Akathisia In Setting Of Comparable Antidepressant Efficacy Constitutes Basis For Accelerated FDA Approval Of Nrx-101

BenzingaMay 6 08:33 ET

Express News | NRX Pharmaceuticals Inc - Statistically Significant Safety Advantage of NRX-101 Compared to Standard of Care

ReutersMay 6 08:31 ET

Express News | NRX Pharmaceuticals Inc - Company Plans to Seek Accelerated Approval of NRX-101 for Use in Patients With Bipolar Depression at Risk of Akathisia

ReutersMay 6 08:30 ET

Express News | NRX Pharmaceuticals Inc - NRX-101 Demonstrated a Mean 76% Reduction in Symptoms of Akathisia Compared to Lurasidone

ReutersMay 6 08:30 ET